Hitting cancer where it hurts.
Two recent studies that involve perturbing tumour blood supply provide new hope for anti-cancer therapies. The first uses elegant molecular engineering to achieve tumour-specific blood clots and the second reports the identification of a natural inhibitor, endostatin, which is produced from tumour extracellular matrix.
Sunassee
K
K
ICRF Laboratory of Molecular Therapy, ICRF Oncology Unit, Hammersmith Hospital, DuCane Road, London, W12 ONN, UK.
Vile
R
R
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001777:Blood Coagulation; D003094:Collagen / Q000096:biosynthesis / Q000627:therapeutic use; D043169:Endostatins; D005109:Extracellular Matrix / Q000473:pathology / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D010446:Peptide Fragments / Q000096:biosynthesis / Q000627:therapeutic use; D015202:Protein Engineering
D000970:Antineoplastic Agents; D043169:Endostatins; D010446:Peptide Fragments; D003094:Collagen